Drug resistance pattern of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients at Isfahan AL Zahra hospital, Iran (2009-2010)
,
Abstract
Background and Objectives: Cystic fibrosis (CF) is an autosomal recessive genetic disease. Infections in these patients gene.are mostly caused by three bacteria: Staphylococcus aureus, Haemophilus influenza and particularly Pseudomonas aeruginosa. Carbapenems including antibiotics are used to combat infections with Pseudomonas aeruginosa. In recent years, carbapenems resistant strains of P. aeruginosa isolated from clinical specimens are being reported. Decrease in drug penetration and production of metalobeta lactamase (MBLS) have been proposed as mechanisms of resistance.
Materials and Methods: In this descriptive study, the population under investigation was 27 patients suffering from CF in Alzahra hospital of Isfahan. Clinical specimens were taken by deep swabbing from throat and data from every patient was recorded in a questionnaire. The specimens were cultured and isolated organisms were identified as P. aeruginosa using standard tests. Kirby-Bauer disk diffusion method was used to determine the bacterial drug resistance pattern. Strains of P. aeruginosa were checked for production of MBLS using disk impregnated with IPM-EDTA and PCR targeting of bla.
Results: Among the 27 patients, 7 (26%) had P. aeruginosa infection. In total, 11 P. gene. aeruginosa isolates were taken. All isolates were susceptible to imipenem, ticarcillin, ciprofloxacin and piperacillin. The lowest scale of susceptibility belonged VIM to eftazidime (72.2%) followed by tobramycin (45.4%). None of the strains were positive for the bla
Conclusion: Isolates of P. aeruginosa from CF patients in Isfahan were susceptible to antibiotics during the study period.
Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J,Niederman MS, et al. Community-acquired pneumonia due to Gram-negative bacteria and P. aeruginosa. Arch Intern Med 2002; 162: 1849-1858.
Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa 3. National Institute of Health. Learning about cystic fibrosis.February 2009; http://www.genome.gov/10001213
Chee LC, Durie P. Genotype and phenotype in cystic fibrosis. Hospit Pract 1997; 15:115-142.
Gilligan PH. Microbiology of airway disease in patient with cystic fibrosis.Clin Micobiol Rev.2002: 4: 35-51.
Walsh TR, Toleman MA, Poirel L, Nordmann P.Metallo-beta-lactamases: the quiet before the storm?2005; 18: 306-325.
Kerem E. The role of Pseudomonas aeruginosa in the pathogenesis of lung disease in cystic fibrosis: more questions than answers. Pediatr Pulmonol 1997; 16 (Suppl): 265-266.
West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, Splaingard MJ, Farrell PM. Respiratory infections with Pseudomonas aeruginosain children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002; 287: 2958-2967.
Spilker T, Coenye T, Vandamme P, LiPuma JJ.PCR-based assay for differentiation of Pseudomonas aeruginosafrom other Pseudomonas species recovered from cystic fibrosis patients. J Clin Microbiol 2004; 42:2074-2079.and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-574.
Ojeniyi B, Frederiksen B, Hoiby N.Pseudomonas aeruginosacross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29: 177-181.
Gillspie SH (2006). Principles and Practice of Clinical Bacteriology. Second edition. Wiley Online.
Webb AK. The treatment of pulmonary infection in cystic fibrosis. Scand J Infect Dis 1995; 96 (Suppl.): 24-27.
Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299-323.
Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27Suppl 2: S24-28.
Mouton JW, den Hollander JG, Horrevorts AM.Emergence of antibiotic resistance amongst Pseudomo- nas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993; 31: 919-926.
Sonnesyn SW,Gerding DN. (1994) Antimicrobials for the treatment of respiratory infections. In: Niedeman MS, Sarosi GA. Glassroth J (Eds) Respiratory infections- A Scientifics Basis for Management, Saunders, Philadelphia, pp. 511-537.
Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double- disk synergy test for differentiating metallo-beta- lactamase producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003; 41: 4623-4629.
Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients. Indian J Med Res 2008; 127: 398-402.
Oh EJ, Lee S, Park YJ, Park JJ, Park K, Kim SI, et al. Prevalence of metallo-betalactamase among Pseudomonas aeruginosa and Acinetobacter baumannii in a Korean university hospital and comparison of screening methods for detecting metallo-betalactamase. J Microbiol Methods 2003; 54: 411-418.
Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol. 2005; 43: 3129-3135.
Mouton JW, den Hollander JG, Horrevorts AM.Emergence of antibiotic resistance amongst Pseudomo- nas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993; 31: 919-926.
Hall BG, Barlow M. Revised Ambler classification of {beta}-lactamases. J Antimicrob Chemother 2005; 55:1050-1051.
Cheng K,Smyth RL, Gvan JR, Doherty C, Winstannley C, Denning N et al. Spread of beta-lactam resistant Pseudomonas aeruginosain a Cystic Fibrosis clinic. Lancet 1996; 348: 639-642.
Xu J, Moore JE, Murphy PG, Millar BC, Elborn JS. Early detection of Pseudomonas aeruginosa--comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF). Ann Clin Microbiol Antimicrob 2004; 3: 21.
Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008; 7: 123-127.
Eftekhar F, Rostamizadeh F, Khodadad A, Henry D, Speert DP. Isolation and genetic fingerprinting of Pseudomonas aeruginosafrom Iranian patients with cystic fibrosis using RAPD-PCR. Iran J Biotech 2003;1: 95-100.
Cardoso O, Alves AF, Leitão R. Metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from a cystic fibrosis patient. Int J Antimicrob Agents 2008;31: 375-379.
Chee LC, P Durie.Genotype and phenotype in cystic fibrosis. Hospit Pract1997; 15: 115-142.
| Files | ||
| Issue | Vol 4 No 2 (2012) | |
| Section | Articles | |
| Keywords | ||
| Cystic fibrosis seudomonas aeruginosa VIM | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
